(218 days)
Not Found
No
The device description focuses on mechanical features for safety and does not mention any computational or data-driven components.
No.
The device is a safety pen needle designed for drug injection with an emphasis on preventing needle sticks, rather than directly treating a disease or condition.
No
The device is a pen needle intended for drug injection, not for diagnosing conditions or diseases.
No
The device description clearly details physical components like needles, hubs, shields, and packaging, indicating it is a hardware medical device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "for use with pen injector devices for the injection of drugs." This describes a device used to administer a substance into the body, not to perform tests on samples taken from the body.
- Device Description: The description details a needle assembly designed for subcutaneous injection and features to prevent needle sticks. This aligns with a drug delivery device, not a diagnostic test.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting analytes, or providing diagnostic information.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The DropSafe Safety Pen Needle's function is solely to facilitate the delivery of medication.
N/A
Intended Use / Indications for Use
The DropSafe Safety Pen Needles are sterile, single-use safety needles intended for use with pen injector devices for the injection of drugs.
Product codes (comma separated list FDA assigned to the subject device)
FMI
Device Description
DropSafe Safety Pen Needles are sterile, single-use safety needles intended for use with pen injector devices for the injection of drugs. DropSafe Safety Pen Needles are OTC devices intended to be used by clinical and non-clinical users. DropSafe Safety Pen Needles are already offered in one gage - 31 G and in two lengths: 6mm and 8 mm. This submission covers the addition of a new length: 5 mm with the same gage - 31G. DropSafe Safety Pen Needles are gamma sterilized, non-toxic single use devices.
The device is designed to minimize the risk from accidental needle sticks with a used needle by application of a sharps injury prevention feature. Following use, the needle is locked out preventing reuse. The shield also serves to hide the needle before and after injection. Each DropSafe safety pen needle is individually packaged in a sealed container. The DropSafe safety pen needle is used by removing the seal and attaching it to the pen injector device to administer a drug subcutaneously. While inserting the needle into the skin at a 90° angle, the slider glides into the shield. While the slider glides into the shield, the safety feature is activated. Following injection, the slides back into its initial position, completely covering the needle where it remains locked. The red safety lock indicator tells the safety lock has been activated. Once the safety pen needle is in the locked mode, it cannot be reused. The safety pen needle is detached from the pen injector device and disposed of into a sharps container.
The pen needle assembly consists of a double-ended cannula that is assembled into an injection molded hub using an adhesive. The hub has internal threads which allows it to be screwed onto the pen injector device. This allows the cartridge end of the needle to penetrate through the rubber septum of the cartridge. The patient-end and the cartridge end of the cannula are lubricated using a silicone-based lubricant for ease of injection and rubber septum penetration.
An injection molded inner shield is assembled over the patient end of the cannula to prevent needle point damage and accidental needle-sticks. This needle assembly is inserted into a protective injection molded container and sealed with a peel away medical grade paper tab which provides a sterility barrier and tamper evident seal.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Body below the surface of the skin (for injection of drugs)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Clinical and non-clinical users
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification/Validation testing was conducted in compliance with the requirements of ISO 11608- 2:2012. All testing met the applicable requirements.
FDA GUIDANCE Medical Devices with Sharps Injury Prevention Features (issued on August 9, 2005). Testing was performed to evaluate the function of the safety feature in a simulated clinical environment with the participation of both clinical and non-clinical users. The Simulated Use Study was performed to validate the Instructions For Use (IFU) with the participation of clinical and non-clinical users. As evidenced in the study, the use of this device does not affect the injection technique or the functionality of the pen injector and is safe and effective when used as per the Instructions for Use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5570 Hypodermic single lumen needle.
(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION" stacked on top of each other.
January 7, 2022
Htl Strefa Sa Justyna Zemigala RA Manager ul. Adamówek 7 Ozorków. 95-035 Poland
Re: K211716
Trade/Device Name: DropSafe Safety Pen Needles Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: Class II Product Code: FMI Dated: November 30, 2021 Received: December 6, 2021
Dear Justyna Zemigala:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
CAPT Alan Stevens Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name
Indications for Use (Describe)
Type of Use (Select one or both, as applicable) | |
---|---|
☐ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
As required by the Safe Medical Devices Act of 1990 and in accordance with 21 CFR ട്ല807.92(a).
[807.92 (a)(1,2)]
| Date Summary
Prepared: | May 26th, 2021 |
---|---|
Submitted By: | HTL-STREFA S.A. |
ul. Adamówek 7 | |
95-035 Ozorków | |
POLAND | |
Phone: +48 42 270 00 10 | |
Fax: +48 42 270 00 20 | |
Primary Contact: | Justyna Żemigała |
RA Manager | |
justyna.zemigala@htl-strefa.pl | |
Secondary Contact: | Izabela Banaś |
Senior RA Specialist | |
izabela.banas@htl-strefa.pl | |
Trade Name: | DropSafe Safety Pen Needles |
Models: | 31G x 5 mm |
Common Name: | Insulin Pen Needle |
Regulation Number: | 21 CFR § 880.5570 |
Product Code: | FMI |
Device Classification: | II |
Review Panel: | 80 General Hospital |
4
Predicate Device [807.92(a)(3)]
The legally marketed devices to which substantial equivalence is claimed is:
Predicate Device:
Manufacturer | Trade Name | 510(k) Number |
---|---|---|
HTL-Strefa S.A. | DropSafe Safety Pen Needle | K170988 |
Description of Device: [807.92(a)(4)]
Device description
DropSafe Safety Pen Needles are sterile, single-use safety needles intended for use with pen injector devices for the injection of drugs. DropSafe Safety Pen Needles are OTC devices intended to be used by clinical and non-clinical users. DropSafe Safety Pen Needles are already offered in one gage - 31 G and in two lengths: 6mm and 8 mm. This submission covers the addition of a new length: 5 mm with the same gage - 31G. DropSafe Safety Pen Needles are gamma sterilized, non-toxic single use devices.
The device is designed to minimize the risk from accidental needle sticks with a used needle by application of a sharps injury prevention feature. Following use, the needle is locked out preventing reuse. The shield also serves to hide the needle before and after injection. Each DropSafe safety pen needle is individually packaged in a sealed container. The DropSafe safety pen needle is used by removing the seal and attaching it to the pen injector device to administer a drug subcutaneously. While inserting the needle into the skin at a 90° angle, the slider glides into the shield. While the slider glides into the shield, the safety feature is activated. Following injection, the slides back into its initial position, completely covering the needle where it remains locked. The red safety lock indicator tells the safety lock has been activated. Once the safety pen needle is in the locked mode, it cannot be reused. The safety pen needle is detached from the pen injector device and disposed of into a sharps container.
The pen needle assembly consists of a double-ended cannula that is assembled into an injection molded hub using an adhesive. The hub has internal threads which allows it to be screwed onto the pen injector device. This allows the cartridge end of the needle to penetrate through the rubber septum of the cartridge. The patient-end and the cartridge end of the cannula are lubricated using a silicone-based lubricant for ease of injection and rubber septum penetration.
An injection molded inner shield is assembled over the patient end of the cannula to prevent needle point damage and accidental needle-sticks. This needle assembly is inserted into a protective injection molded container and sealed with a peel away medical grade paper tab which provides a sterility barrier and tamper evident seal.
5
Indications for Use: [807.92(a)(5)]
The DropSafe Safety Pen Needles are sterile, single-use safety needles intended for use with pen injector devices for the injection of drugs.
Technological Characteristics: [807.92(a)(6)]
A comparison of characteristics of DropSafe Safety Pen Needles and the predicate device is shown in the table below:
Device Name | New Device | Predicate Device |
---|---|---|
Manufacturer | HTL-STREFA S.A. | HTL-STREFA S.A. |
510(k) Number | K211716 | K170988 |
Brand name | DropSafe Safety Pen Needle | DropSafe Safety Pen Needle |
Intended use | Intended for use with pen injector | |
devices for the injection of drugs | Intended for use with pen injector | |
devices for the injection of drugs | ||
Operation principle | Manual | Manual |
Design | Needle assembly - | |
cannula, hub, primary container, | ||
seal, needle shield, slider, plug, | ||
spring- operated | Needle assembly - | |
cannula, hub, primary container, | ||
seal, needle shield, slider, plug, spring- | ||
operated | ||
Product Code | FMI | FMI |
Length | 5 mm | 6mm, 8 mm |
Gage | 31G | 31G |
Biocompatibility | Conforms to | |
ISO 10993-1 & USP Method 1 | Conforms to ISO | |
10993-1 | ||
Sterilization | Gamma radiation | Gamma radiation |
Needle tube | Medical Grade Stainless Steel | Medical Grade Stainless Steel |
Hub, Primary | ||
Container, | ||
Shield, Plug | Plastic resin | Plastic resin |
Spring | Stainless steel wire | Stainless steel wire |
6
The new device and the predicate device are classified under 21 CFR 880.5570, which states: "A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin." The indications for use of the new device and the predicate and devices is identical (intended for use with pen injector devices for the injection of drugs).
The only difference between the new device and the predicate device is the needle length on patient end. The new device is 5 mm, whereas the already cleared versions are 6mm and 8mm.
The production process, sterilization process, production facilities and conditions, operation principle, biocompatibility and shelf life aspects are identical for the new and predicate device.
The difference in needle length on patient end between the new device and the predicate device does not raise any new or different questions of safety or effectiveness.
7
Non-Clinical Performance Data:
[(807.92(b)(1)]
Verification/Validation testing was conducted in compliance with the requirements of ISO 11608- 2:2012 as summarized below. All testing met the applicable requirements.
| Parameters and clause
from ISO 11608-2:2012 | Requirements | Result |
---|---|---|
4.1 Materials | The needle shall be made of tubing | |
materials specified in ISO 9626 | Meets standard | |
4.2.2 Dimensions | Needles shall fit the test apparatus | |
specified in item 7.3 of ISO 11608-2. | ||
Dimensions shall be in accordance with | Meets standard | |
4.3 Determination of | ||
flow rate through the | ||
needle | The flow rate is at the border: min 2,14 | |
ml/min | Meets standard | |
4.4 Bond between hub | ||
and needle tube | Clause 9 of ISO 11608-2 and clause 13.1. | |
The union of the hub and needle tube | ||
shall not break for at least 5 sec. while a | ||
force of at least 11 N is applied | Meets standard | |
4.5 Needle points | Visually under a magnification of x2,5, | |
needle points shall appear sharp and free | ||
from feather edges, burrs and hooks | Meets standard | |
4.6 Freedom from defects | Visually inspected by normal or | |
corrected-to-normal vision without | ||
magnification under an illuminance of | ||
300 lx to 700 lx, the outer surface of the | ||
tubing shall be smooth and free from | Meets standard | |
4.7 Lubrication | No visible droplets on the outside surface | |
of the | Meets standard | |
4.8 Dislocation of | ||
measuring point at | ||
patient end | Clause 8 of ISO 11608-2:2012 maximum | |
allowable dislocation acc. Clause 4.8, | ||
Table 2 for 5mm: 0.65m | Meets standard | |
4.9 Determination of | ||
functional compatibility | ||
with needle-based | Clause 11 of ISO 11608-2:2012 | |
Needle assembly torque: 0.07 +/- 0.01 | ||
Nm Needle hub removal: less than 0.100 | Meets standard | |
4.10 Ease of assembly | ||
and disassembly | Nm Dose accuracy: for doses ≤ 20 ml the | |
calculated values were within ± 0.01 ml | ||
of the targeted dose; for doses > 20 ml the | ||
calculated values were within ± 5 % of | ||
the targeted dose | Meets standard | |
4.11 Sterility | The needle in its unit packaging has | |
undergone an approved sterilization | ||
process. Sterilization method: Gamma | ||
irradiation. Sterilization conditions 17,5- | ||
40kGy. | Meets standard | |
6. Pre-conditioning of | ||
needles | All pen safety needles to in tested were | |
preconditioned atmosphere in: a dry-heat, | ||
a cold-storage, a cyclical atmosphere. | ||
Prepared in accordance with the | ||
requirements specified in clauses 6.1, 6.2, | ||
6.3 of ISO 11608-2: 2012 | Meets standard | |
12.2.1 Marking on the | ||
unit packaging | Any marking on the unit packaging that is | |
essential for the safe use of the NIS shall | ||
be visible and easily legible | Meets standard | |
12.2.2 Marking on the | ||
unit packaging | The marking on the unit packaging shall | |
comprise at least the particulars listed in | ||
ISO 11608-2:2012 item 12.2.2 | Meets standard | |
12.2.3 Marking on the | ||
user packaging | The marking on the user packaging shall | |
comprise at least the particulars listed in | ||
ISO 11608-2:2012 item 12.2.3 | Meets standard |
8
9
Clinical Performance Data:
[(807.92(b)(2)]
FDA GUIDANCE Medical Devices with Sharps Injury Prevention Features (issued on August 9, 2005).
Testing was performed to evaluate the function of the safety feature in a simulated clinical environment with the participation of both clinical and non-clinical users. The Simulated Use Study was performed to validate the Instructions For Use (IFU) with the participation of clinical and non-clinical users. As evidenced in the study, the use of this device does not affect the injection technique or the functionality of the pen injector and is safe and effective when used as per the Instructions for Use.
Conclusion:
[(807.92(b)(3)]
DropSafe Safety Pen Needle 5mm is substantially equivalent in the intended use, technology/principle of operation, materials and performance to the predicate device and does not raise any new questions of safety and effectiveness.